Hosted on MSN7d
Valneva announces positive outcomes from chikungunya vaccine trial
Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...
Hosted on MSN7d
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
Valneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents (12 to 17 ...
Baylor College of Medicine1y
Chikungunya Virus
Chikungunya is a disease that is caused by the chikungunya virus which is transmitted to humans by infected mosquitoes. Its name is derived from a word in the Makonde language that means contorted or ...
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...
pharmaphorum1y
Bavarian Nordic preps chikungunya vaccine filings
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second phase 3 trial, in hot ...
Medscape6d
Rapid and Real-time Assays for Detection and Quantification of Chikungunya Virus
Future Virology. 2008;3(2):179-192. Although not listed as a hemorrhagic fever virus, illness caused by CHIKV can be confused with diseases such as dengue or yellow fever, based on the similarity ...